TheraRadar
Data updated: May 26, 2026

HEMABATE (carboprost tromethamine)

Women's Health Approved 1979-01-09

HEMABATE is indicated for the treatment of Postpartum Hemorrhage; Uterine Atony.

Source: FDA Label • Pfizer
1
Indication
--
Phase 3 Trials
47
Years on Market

Details

Status
Prescription
First Approved
1979-01-09
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: CARBOPROST TROMETHAMINE

HEMABATE Approval History

1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
18 FDA actions from 1979 to 2015
Jun 2015 SUPPL
Mfg · Manufacturing (CMC)
Jun 2014 SUPPL
Mfg · Manufacturing (CMC)
Dec 2013 SUPPL
Label · Labeling

What HEMABATE Treats

2 indications

HEMABATE is approved for 2 conditions since its original approval in 1979. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Postpartum Hemorrhage
  • Uterine Atony
Source: FDA Label

HEMABATE Boxed Warning

WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities....

HEMABATE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

2

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to HEMABATE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CARBOPROST TROMETHAMINE
CARBOPROST TROMETHAMINE
2 shared
EUGIA PHARMA
Shared indications:
Postpartum HemorrhageUterine Atony
METHYLERGONOVINE MALEATE
METHYLERGONOVINE MALEATE
1 shared
AM REGENT
Shared indications:
Uterine Atony
PITOCIN
OXYTOCIN
1 shared
PH HEALTH
Shared indications:
Postpartum Hemorrhage
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HEMABATE FDA Label Details

Indications & Usage

FDA Label (PDF)

HEMABATE is indicated for the treatment of Postpartum Hemorrhage; Uterine Atony.

⚠️ BOXED WARNING

WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facili...

Track HEMABATE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.